Description

Rozanolixizumab is a monoclonal antibody that targets the neonatal Fc receptor (FcRn), which plays a crucial role in regulating the levels of immunoglobulin G (IgG) in the body. It is being investigated for its potential use in treating autoimmune diseases by modulating the immune response.

Interpreter Notes

Interpreters should be aware that 'rozanolixizumab' may be pronounced differently in various regions, but it is essential to maintain the clinical term in formal contexts. Colloquial terms or abbreviations should be avoided to ensure clarity and accuracy in communication.

Example Sentences

EN: The clinical trial for rozanolixizumab showed promising results in reducing antibody levels in patients with autoimmune disorders.

ES: El ensayo clínico para rozanolixizumab mostró resultados prometedores en la reducción de los niveles de anticuerpos en pacientes con trastornos autoinmunitarios.

Common Interpreter Mistakes

Confusing 'rozanolixizumab' with similar-sounding medications; mispronouncing 'rozanolixizumab' due to unfamiliarity; using informal language instead of the clinical term.